The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner - PubMed (original) (raw)

The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner

E A Holley-Guthrie et al. J Virol. 1990 Aug.

Abstract

The Epstein-Barr virus early antigen diffuse component (EA-D) is essential for Epstein-Barr virus DNA polymerase activity, and its activity is suppressed during latent infection. We investigated the regulation of the promoter (BMRF1) for this early gene by studying its responsiveness in vitro to two immediate-early viral transactivators, BZLF1 (Z) and BRLF1 (R), focusing on the differences in response in lymphoid cells and epithelial cells. In lymphoid cells, Z or R alone produced only small increases in EA-D promoter activity, whereas both transactivators together produced a large stimulatory effect. In epithelial cells, the Z transactivator alone produced maximal stimulation of the EA-D promoter; the effect of R and Z together was no greater than that of Z alone. Deletional analysis and site-directed mutagenesis of the EA-D promoter demonstrated that in epithelial cells the potential AP-1 binding site plays an essential role in Z responsiveness, although sequences further upstream are also important. In lymphoid cells, only the upstream sequences are required for transactivation by the Z/R combination, and the AP-1 site is dispensable. These data suggest that EA-D (BMRF1) promoter regulation by Z and R is cell type specific and appears to involve different mechanisms in each cell type.

PubMed Disclaimer

Similar articles

• Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1.
  Quinlivan EB, Holley-Guthrie EA, Norris M, Gutsch D, Bachenheimer SL, Kenney SC. Quinlivan EB, et al. Nucleic Acids Res. 1993 Jul 11;21(14):1999-2007. doi: 10.1093/nar/21.8.1999. Nucleic Acids Res. 1993. PMID: 8393562 Free PMC article.
• The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factor.
  Zalani S, Holley-Guthrie EA, Gutsch DE, Kenney SC. Zalani S, et al. J Virol. 1992 Dec;66(12):7282-92. doi: 10.1128/JVI.66.12.7282-7292.1992. J Virol. 1992. PMID: 1331521 Free PMC article.
• Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection.
  Sista ND, Pagano JS, Liao W, Kenney S. Sista ND, et al. Proc Natl Acad Sci U S A. 1993 May 1;90(9):3894-8. doi: 10.1073/pnas.90.9.3894. Proc Natl Acad Sci U S A. 1993. PMID: 8387200 Free PMC article.
• The SWI/SNF Chromatin Regulator BRG1 Modulates the Transcriptional Regulatory Activity of the Epstein-Barr Virus DNA Polymerase Processivity Factor BMRF1.
  Su MT, Wang YT, Chen YJ, Lin SF, Tsai CH, Chen MR. Su MT, et al. J Virol. 2017 Apr 13;91(9):e02114-16. doi: 10.1128/JVI.02114-16. Print 2017 May 1. J Virol. 2017. PMID: 28228591 Free PMC article.
• Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product.
  Adamson AL, Kenney SC. Adamson AL, et al. Virology. 1998 Nov 10;251(1):187-97. doi: 10.1006/viro.1998.9396. Virology. 1998. PMID: 9813214

Cited by

• Epstein-Barr Virus Viral Processivity Factor EA-D Facilitates Virus Lytic Replication by Inducing Poly(ADP-Ribose) Polymerase 1 Degradation.
  Lee S, Kim J, Chung WC, Han JH, Song MJ. Lee S, et al. J Virol. 2022 Nov 9;96(21):e0037122. doi: 10.1128/jvi.00371-22. Epub 2022 Oct 26. J Virol. 2022. PMID: 36286483 Free PMC article.
• Rta is the principal activator of Epstein-Barr virus epithelial lytic transcription.
  Ali A, Ohashi M, Casco A, Djavadian R, Eichelberg M, Kenney SC, Johannsen E. Ali A, et al. PLoS Pathog. 2022 Sep 29;18(9):e1010886. doi: 10.1371/journal.ppat.1010886. eCollection 2022 Sep. PLoS Pathog. 2022. PMID: 36174106 Free PMC article.
• ΔNp63α promotes Epstein-Barr virus latency in undifferentiated epithelial cells.
  Van Sciver N, Ohashi M, Nawandar DM, Pauly NP, Lee D, Makielski KR, Bristol JA, Tsao SW, Lambert PF, Johannsen EC, Kenney SC. Van Sciver N, et al. PLoS Pathog. 2021 Nov 8;17(11):e1010045. doi: 10.1371/journal.ppat.1010045. eCollection 2021 Nov. PLoS Pathog. 2021. PMID: 34748616 Free PMC article.
• Direct Evidence of Abortive Lytic Infection-Mediated Establishment of Epstein-Barr Virus Latency During B-Cell Infection.
  Inagaki T, Sato Y, Ito J, Takaki M, Okuno Y, Yaguchi M, Masud HMAA, Watanabe T, Sato K, Iwami S, Murata T, Kimura H. Inagaki T, et al. Front Microbiol. 2021 Jan 21;11:575255. doi: 10.3389/fmicb.2020.575255. eCollection 2020. Front Microbiol. 2021. PMID: 33613459 Free PMC article.
• Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals.
  Shindiapina P, Ahmed EH, Mozhenkova A, Abebe T, Baiocchi RA. Shindiapina P, et al. Front Oncol. 2020 Sep 30;10:1723. doi: 10.3389/fonc.2020.01723. eCollection 2020. Front Oncol. 2020. PMID: 33102204 Free PMC article. Review.

References

1. 1. Science. 1982 Jul 23;217(4557):316-24 - PubMed
2. 1. Nature. 1988 Jun 2;333(6172):455-7 - PubMed
3. 1. J Virol. 1984 Jan;49(1):183-9 - PubMed
4. 1. N Engl J Med. 1984 May 10;310(19):1225-30 - PubMed
5. 1. Proc Natl Acad Sci U S A. 1985 Jan;82(2):488-92 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central